Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

3(42.9%)

7Total

Phase 1(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05660642Phase 2Recruiting

An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

Role: lead

NCT05674929Phase 2Completed

An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

Role: lead

NCT05870540Phase 2Completed

BPL-003 Efficacy and Safety in Treatment Resistant Depression

Role: lead

NCT05434156Phase 1Active Not Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Role: collaborator

NCT05347849Phase 1Completed

Single Ascending Dose Study With BPL-003 in Healthy Subjects

Role: lead

NCT04905121Phase 1Terminated

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Role: lead

NCT05032833Phase 1Completed

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

Role: lead

All 7 trials loaded